IL13RA2 and glioblastoma: The investigators reported one case of a patient with recurrent GBM who received multiple infusions of the modified IL13Rα2 CAR T cell into the resected tumor bed, and was found to have regression of all intracranial and spinal tumors that lasted for 7.5 months [85].